Reuters (1/27, Basu) reported Infinity Pharmaceuticals has stopped a mid-stage trial of an experimental pancreatic cancer medicine known as saridegib because a preliminary analysis showed that patients receiving placebo plus an anti-cancer chemotherapy treatment survived longer than those on saridegib and chemotherapy. The trial included some 122 patients with metastatic pancreatic cancer who did not receive prior treatment. Infinity is also developing a non-small cell lung cancer drug, known as retaspimycin hydrochloride, which is currently in mid-stage trial
